epididymal protein 3C, pseudogeneGenealiases: FAM12CP · HE3-GAMMA
Q-omics provides the consensus-scored EDDM3CP profile across patient tissues and cancer cell-line models. EDDM3CP expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, EDDM3CP is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, EDDM3CP RNA expression shows 5,944 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight THCA, STAD, and PDAC as cancer lineages where EDDM3CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDDM3CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDDM3CP survival associations across molecular data types. EDDM3CP RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDDM3CP RNA expression–survival associations across cancer types. High EDDM3CP expression shows unfavorable associations in THCA, MESO, DLBC, BLCA, SARC and KIRP. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for EDDM3CP RNA expression.
This table summarizes EDDM3CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for EDDM3CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDDM3CP shows higher tumor expression in STAD. The STAD box plot shows higher EDDM3CP RNA expression in tumor versus normal tissue (log2 FC = +0.055, t-test p = .005).
This table shows molecular features associated with EDDM3CP in patient tissues and cancer cell lines. In patient samples, EDDM3CP shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
